Estimation of hematological parameters and lipid profile of coronary artery disease patients with Helicobacter pylori


  • Muntadher Alhasan University of Thi-Qar, College of Science, Department of Biology
  • Manal Badi Salih College of Science/ University of Thi-Qar



H.pylori, coronary artery disease, lipid profile


Helicobacter pylori infection causes generally gastric illnesses, however from the beginning of 1994, a few researchers have detailed a relationship of H. pylori with other systemic manifestations are outside stomach include various extra gastric appearances, for e.g., neurological, dermatological, hematologic, visual, cardiovascular, metabolic, hypersensitive, and hepatobiliary diseases. In this study, blood parameters, lipid profile, and fasting glucose were measured for patients with coronary artery disease with H. pylori, and the relationship of H. pylori with lipids, which is considered a risk factor for coronary artery disease, was measured. 150 people participated in the current study, and they were divided into three groups: The first group had arterial disease. coronary artery disease with H. pylori 50 people, the second group had coronary artery disease without H. pylori 50 people, the third group the control group 50 people. The samples were obtained from the heart center in Nasiriyah. Risk factors were taken into account: which included age, gender, smoking status, high blood pressure, and diabetes. In the first group, the number of males was 28 (56%) and females 22 (44%) with an average age of 72.60 ± 18.97, the second group had a number of males 33 (66%) and females 17 (34%) with an average age of 71.70 ± 21.06, the third group the number of males was 28 (56%) and females 22 (44%) with an average age of 55.44 ± 18.53. 


A. Onat et al., “Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study,” Metabolism., vol. 56, no. 3, pp. 348–356, 2007, doi: 10.1016/j.metabol.2006.10.016.

J. Vafaeimanesh, S. F. Hejazi, V. Damanpak, M. Vahedian, M. Sattari, and M. Seyyedmajidi, “Association of helicobacter pylori infection with coronary artery disease: Is helicobacter pylori a risk factor?,” Sci. World J., vol. 2014, 2014, doi: 10.1155/2014/516354.

G. H. Dahlén, J. Boman, L. S. Birgander, and B. Lindblom, “Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease,” Atherosclerosis, vol. 114, no. 2, pp. 165–174, 1995, doi: 10.1016/0021-9150(94)05480-7.

J. I. Elizalde et al., “Platelet activation in mice and human Helicobacter pylori infection,” J. Clin. Invest., vol. 100, no. 5, pp. 996–1005, 1997, doi: 10.1172/JCI119650.

B. Factors, “REVIEWS IN BASIC AND CLINICAL,” pp. 306–323, 2008, doi: 10.1053/j.gastro.2007.11.009.

J. Sasaki et al., “Gender difference in coronary events in relation to risk factors in Japanese hypercholesterolemic patients treated with low-dose simvastatin,” Circ. J., vol. 70, no. 7, pp. 810–814, 2006, doi: 10.1253/circj.70.810.

P. Cullen and G. Assmann, “High risk strategies for atherosclerosis,” Clin. Chim. Acta, vol. 286, no. 1–2, pp. 31–45, 1999, doi: 10.1016/S0009-8981(99)00092-3.

B. M. Kadhim, M. B. Salih, and H. S. Abdulhussein, “Molecular Detection of Helicobacter pylori by Real Time- PCR in Dyspeptic Patients Abstract :,” vol. 6, no. 4, 2018.

B. L. Smoak, P. W. Kelley, and D. N. Taylor, “Seroprevalence of Helicobacter pylori infections in a cohort of US army recruits,” Am. J. Epidemiol., vol. 139, no. 5, pp. 513–519, 1994, doi: 10.1093/oxfordjournals.aje.a117034.

M. Ferrara, L. Capozzi, and R. Russo, “Effect of helicobacter pylori eradication on platelet count in children with chronic idiopathic thrombocytopenic purpura,” Hematology, vol. 14, no. 5, pp. 282–285, 2009, doi: 10.1179/102453309X12473408860181.

A. Prasad, J. Zhu, J. P. J. Halcox, M. A. Waclawiw, S. E. Epstein, and A. A. Quyyumi, “Predisposition to atherosclerosis by infections: Role of endothelial dysfunction,” Circulation, vol. 106, no. 2, pp. 184–190, 2002, doi: 10.1161/01.CIR.0000021125.83697.21.

H. Scharnagl, M. Kist, A. B. Grawitz, W. Koenig, H. Wieland, and W. März, “Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol,” Am. J. Cardiol., vol. 93, no. 2, pp. 219–220, 2004, doi: 10.1016/j.amjcard.2003.09.045.

M. Yucel and S. Boyacioglu, “Does Eradication of Helicobacter pylori Infection Help Normalize Serum Lipid and CRP Levels ?,” no. May 2018, 2005, doi: 10.1007/s10620-005-2764-9.

C. Y. Jeon et al., “Helicobacter pylori infection is associated with an increased rate of diabetes,” Diabetes Care, vol. 35, no. 3, pp. 520–525, 2012, doi: 10.2337/dc11-1043.

M. Madjid and O. Fatemi, “Components of the complete blood count as risk predictors for coronary heart disease: In-depth review and update,” Texas Hear. Inst. J., vol. 40, no. 1, pp. 17–29, 2013.

D. S. Mahdi, M. Thameraltemimi, A. Endocrinologist, S. D. Endocrine, and H. Directorate, “The Prediction of Macrovascular Complications in Individuals with Type 2 diabetes mellitus with Different Risk Factors in ThiQar,” vol. 1, no. 1, 2023.

C. Ciacci et al., “Helicobacter pylori impairs iron absorption in infected individuals,” vol. 36, pp. 455–460, 2004, doi: 10.1016/j.dld.2004.02.008.

S. Kim, M. Eliot, D. C. Koestler, W. C. Wu, and K. T. Kelsey, “Association of neutrophil-to-lymphocyte ratio with mortality and cardiovascular disease in the jackson heart study and modification by the duffy antigen variant,” JAMA Cardiol., vol. 3, no. 6, pp. 455–462, 2018, doi: 10.1001/jamacardio.2018.1042.

H. A. H. Abu-Zeid and J. M. Chapman, “Hemoglobin level and ischemic heart disease: Relationship to known risk factors,” Prev. Med. (Baltim)., vol. 6, no. 1, pp. 120–129, 1977, doi: 10.1016/0091-7435(77)90009-3.

R. C. Schlant, S. Forman, J. Stamler, and P. L. Canner, “The natural history of coronary heart disease: Prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project,” Circulation, vol. 66, no. 2 I, pp. 401–414, 1982, doi: 10.1161/01.CIR.66.2.401.

D. W. Brown, W. H. Giles, and J. B. Croft, “Hematocrit and the risk of coronary heart disease mortality,” Am. Heart J., vol. 142, no. 4, pp. 657–663, 2001, doi: 10.1067/mhj.2001.118467.

M. Franchini, M. Cruciani, C. Mengoli, G. Pizzolo, and D. Veneri, “Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: A systematic review and meta-analysis,” J. Antimicrob. Chemother., vol. 60, no. 2, pp. 237–246, 2007, doi: 10.1093/jac/dkm195.

P. C. Elwood, A. D. Beswick, D. S. Sharp, J. W. G. Yarnell, S. Rogers, and S. Renaud, “Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly Collaborative Heart Disease Study,” Arteriosclerosis, vol. 10, no. 6, pp. 1032–1036, 1990, doi: 10.1161/01.atv.10.6.1032.

G. Y. H. Lip, “Target organ damage and the prothrombotic state in hypertension,” Hypertension, vol. 36, no. 6, pp. 975–977, 2000, doi: 10.1161/01.HYP.36.6.975.

M. Yazici, A. Kaya, Y. Kaya, S. Albayrak, H. Cinemre, and H. Ozhan, “Lifestyle modification decreases the mean platelet volume in prehypertensive patients,” Platelets, vol. 20, no. 1, pp. 58–63, 2009, doi: 10.1080/09537100802613449.

L. E. Charles, D. Fekedulegn, T. McCall, C. M. Burchfiel, M. E. Andrew, and J. M. Violanti, “Obesity, white blood cell counts, and platelet counts among police officers,” Obesity, vol. 15, no. 11, pp. 2846–2854, 2007, doi: 10.1038/oby.2007.338.

J. T. George, P. K. Boughan, H. Karageorgiou, and M. Bajaj-Elliott, “Host anti-microbial response to Helicobacter pylori infection,” Mol. Immunol., vol. 40, no. 7, pp. 451–456, 2003, doi: 10.1016/S0161-5890(03)00158-5.

K. Robinson, R. H. Argent, and J. C. Atherton, “The inflammatory and immune response to Helicobacter pylori infection,” Best Pract. Res. Clin. Gastroenterol., vol. 21, no. 2, pp. 237–259, 2007, doi: 10.1016/j.bpg.2007.01.001.

S. Lavi et al., “Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease,” Circulation, vol. 115, no. 20, pp. 2621–2627, 2007, doi: 10.1161/CIRCULATIONAHA.106.641654.

T. Bhat, H. Bhat, M. Raza, G. Khoueiry, M. Meghani, and M. Akhtar, “Neutrophil to lymphocyte ratio and cardiovascular diseases : a review,” Expert Rev. Cardiovasc. Ther., vol. 11, no. 1, pp. 55–60, 2013.

L. Guasti et al., “Neutrophils and clinical outcomes in patients with acute coronary syndromes and/or cardiac revascularization: A systematic review on more than 34,000 subjects,” Thromb. Haemost., vol. 106, no. 4, pp. 591–599, 2011, doi: 10.1160/TH11-02-0096.

C. Weber, A. Zernecke, and P. Libby, “The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models,” Nat. Rev. Immunol., vol. 8, no. 10, pp. 802–815, 2008, doi: 10.1038/nri2415.

L. Yao, K. Huang, D. Huang, J. Wang, H. Guo, and Y. Liao, “Acute myocardial infarction induced increases in plasma tumor necrosis factor-α and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell,” Int. J. Cardiol., vol. 123, no. 3, pp. 366–368, 2008, doi: 10.1016/j.ijcard.2007.06.069.

J. Mestas and K. Ley, “Monocyte-Endothelial Cell Interactions in the Development of Atherosclerosis,” Trends Cardiovasc. Med., vol. 18, no. 6, pp. 228–232, 2008, doi: 10.1016/j.tcm.2008.11.004.

N. G. Kounis, G. D. Soufras, G. Tsigkas, and G. Hahalis, “White Blood Cell Counts , Leukocyte Ratios , and Eosinophils as Inflammatory Markers in Patients With Coronary Artery Disease,” 2015, doi: 10.1177/1076029614531449.

Y. M. Æ. F. Levi-schaffer, “Mast cells and eosinophils : the two key effector cells in allergic inflammation,” 2009, doi: 10.1007/s00011-009-0042-6.

N. George, K. Periklis, G. Hahalis, and A. Mazarakis, “The heart seems to be the primary site and the target of anaphylaxis resulting in the development of Kounis syndrome,” vol. l, pp. 119–120, 2012, doi: 10.1007/s11739-012-0786-9.

R. C. Schlant, “The Natural History of Coronary Heart Disease : Prognostic Factors After Recovery from Myocardial Infarction in 2789 Men,” 1974.

P. Keul, A. Polzin, K. Kaiser, M. Gr, and L. Dannenberg, “Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P : a new aspect of HDL dysfunction and its therapy,” pp. 1–14, 2018, doi: 10.1096/fj.201801245R.

T. Duparc et al., “Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study,” Sci. Rep., vol. 10, no. 1, pp. 1–12, 2020, doi: 10.1038/s41598-020-65100-2.

M. Femlak, A. Gluba-Brzózka, A. Ciałkowska-Rysz, and J. Rysz, “The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk,” Lipids Health Dis., vol. 16, no. 1, pp. 1–9, 2017, doi: 10.1186/s12944-017-0594-3.

B. M. He, S. P. Zhao, and Z. Y. Peng, “Effects of cigarette smoking on HDL quantity and function: Implications for atherosclerosis,” J. Cell. Biochem., vol. 114, no. 11, pp. 2431–2436, 2013, doi: 10.1002/jcb.24581.

X. Guo and L. Ma, “Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol-related inflammatory parameters as predictors,” Coron. Artery Dis., vol. 34, no. 1, pp. 66–77, 2023, doi: 10.1097/MCA.0000000000001198.

E. j. Cassel, “The New England Journal of Medicine Downloaded from at PARTNERS HEALTHCARE on October 20, 2010. For personal use only. No other uses without permission. From the NEJM Archive Copyright © 2010 Massachusetts Medical Society.,” 2010.

A. V. A. N. D. E. Regulatie and V. A. N. L. Lipase, “ASPECTS OF THE REGULATION OF LIVER LIPASE,” no. december, 1986.

A. Huang, X. Qi, L. Wei, M. Zhang, and S. Zhou, “Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes,” Cardiol. Res. Pract., vol. 2019, 2019, doi: 10.1155/2019/5931975.

R. Yang, G. Le, D. Ph, A. Li, J. Zheng, and Y. Shi, “Effect of antioxidant capacity on blood lipid metabolism and lipoprotein lipase activity of rats fed a high-fat diet,” vol. 22, pp. 1185–1191, 2006, doi: 10.1016/j.nut.2006.08.018.

B. J. G. Mb and C. Dphil, “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials,” Medicine (Baltimore)., vol. 2011, pp. 359–360, 2010, doi: 10.1016/S0084-3873(11)00278-1.

M. M. Ibrahim, A. Ibrahim, K. Shaheen, and M. A. Nour, “Lipid profile in Egyptian patients with coronary artery disease,” Egypt. Hear. J., vol. 65, no. 2, pp. 79–85, 2013, doi: 10.1016/j.ehj.2012.08.005.

S. A. Hamed et al., “Vascular Risks and Complications in Diabetes Mellitus : The Role of Helicobacter Pylori Infection,” vol. 17, no. 2, pp. 86–94, 2008, doi: 10.1016/j.jstrokecerebrovasdis.2007.10.006.

M. Riad, “Association of Helicobacter pylori infection with coronary artery disease: is it an independent risk factor?,” Egypt. Hear. J., vol. 73, no. 1, 2021, doi: 10.1186/s43044-021-00185-2.

M. Haeri, M. Parham, N. Habibi, and J. Vafaeimanesh, “ Effect of Helicobacter pylori Infection on Serum Lipid Profile ,” J. Lipids, vol. 2018, pp. 1–5, 2018, doi: 10.1155/2018/6734809.

J. Vafaeimanesh, M. Parham, M. Seyyedmajidi, and M. Bagherzadeh, “Helicobacter pylori infection and insulin resistance in diabetic and nondiabetic population,” Sci. World J., vol. 2014, 2014, doi: 10.1155/2014/391250.

K. Mansori et al., “Helicobacter pylori infection as a risk factor for diabetes: A meta-analysis of case-control studies,” BMC Gastroenterol., vol. 20, no. 1, pp. 1–14, 2020, doi: 10.1186/s12876-020-01223-0.








How to Cite

Estimation of hematological parameters and lipid profile of coronary artery disease patients with Helicobacter pylori. (2023). University of Thi-Qar Journal of Science, 10(2), 41-48.